Aura Biosciences Inc. (AURA)

4.97

-0.39 (-7.28%)

At close: Apr 10, 2025, 12:10 PM

Company Description

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer.

The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology.

It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.

It also develops AU-011 in additional ocular oncology indications, including choroidal metastases.

The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Aura Biosciences Inc.

Address: 85 Bolton Street Cambridge, Massachusetts United States
Website	https://www.aurabiosciences.com

Name	Position
Dr. Elisabet de los Pinos Ph.D.	Founder, Chief Executive Officer, President & Director
Dr. Mark Plavsic D.V.M., Ph.D.	Chief Technology Officer
Amy Elazzouzi	Interim Principal Financial Officer & Interim Principal Accounting Officer
Conor Kilroy	General Counsel & Secretary
Dr. Anthony Daniels M.D.	Vice President & Therapeutic Area of Head Ocular Oncology
Dr. Jill J. Hopkins M.D.	Chief Medical Officer & President of Research and Development
Dr. Richard Mountfield Ph.D.	Senior Vice President of Regulatory Affairs & Quality
Dr. Sabine Brookman-May	Senior Vice President & Therapeutic Area Head of Urologic Oncology
Patrick Nealon	Senior Vice President of Clinical Development Operations